SeptiCyte™ LAB Outperforms Other Parameters for Distinguishing Sepsis in Data Presented at the American Thoracic Society International Conference

SEATTLE, May 18, 2016 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that SeptiCyte™ LAB outperformed other clinical and laboratory parameters at distinguishing infection-negative systemic inflammation response syndrome (SIRS) from infection-positive systemic inflammation (sepsis). The data from the VENUS study were presented by Dr. Russell R. Miller, III of Intermountain Medical Center at the American Thoracic Society International Conference in San Francisco.

Dr. Miller's presentation describes the relative performance of various clinical and laboratory parameters, individually and in combination, compared to SeptiCyte™ LAB. SeptiCyte™ LAB performed better at distinguishing SIRS from sepsis than any combination of variables. Additionally, the inclusion of other variables with SeptiCyte™ scores did not improve its diagnostic accuracy.

"Dr. Miller's results indicate that SeptiCyte™ alone provides better information for distinguishing SIRS from sepsis than other clinical and laboratory parameters," said Dr. Roslyn Brandon, President and CEO of Immunexpress. "This research indicates that analyzing a patient's immune response provides a clear solution to the major issue of quickly and effectively diagnosing sepsis."

Sepsis is a life-threatening condition that arises when the body's response to infection damages its own tissues and organs. Diagnosis of sepsis today relies on medical impression based on a combination of clinical parameters and later pathogen detection and therefore has serious limitations in respect to speed and sensitivity. The Immunexpress SeptiCyte™ LAB solution evaluates the patient's own immune response to infection to aid clinicians in quickly and accurately diagnosing sepsis in patients suspected of sepsis.

About Immunexpress

Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients with sepsis and suspected of sepsis. Immunexpress's SeptiCyte™ technology quantifies directly from whole blood specific molecular markers from the patient's own immune system. Detecting the patient's septic immune response has the potential to identify sepsis earlier, faster and more accurately than current sepsis diagnostics that focus on identifying the invading pathogen; the immune response is independent of whether or not the pathogen is in the blood sample. Immunexpress's pipeline includes assays for readily available lab-based platforms, as well as point-of-care (POC) sample-to-answer instrumentation. For more information visit www.Immunexpress.com.

Follow Immunexpress on Twitter at twitter.com/Immunexpress and LinkedIn at www.linkedin.com/company/immunexpress-inc.

Media Contacts:
David Schull or Todd Davenport, Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4262
[email protected]
[email protected]

SOURCE Immunexpress, Inc.